Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

 Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare
                                  Conference

PR Newswire

BRIDGEWATER, N.J., Jan. 4, 2013

BRIDGEWATER, N.J., Jan. 4, 2013 /PRNewswire/ --Savient Pharmaceuticals, Inc.
(NASDAQ: SVNT) today announced that Lou Ferrari, President and Chief Executive
Officer, will present at the 31^st Annual J.P. Morgan Healthcare Conference on
Thursday, January 10, 2013, at 12:00 p.m. Pacific Time. The conference will
be held at the Westin St. Francis Hotel in San Francisco, CA.

A live webcast of the presentation can be accessed through the investor
relations section of the Company's website atwww.savient.com. Following the
live presentation, a replay of the webcast will be available on the Company's
website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused
on developing and commercializing KRYSTEXXA^® (pegloticase) for the treatment
of chronic gout in adult patients who do not respond to conventional therapy.
Savient has exclusively licensed worldwide rights to the technology related to
KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View
Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme
and MVP developed the PEGylation technology used in the manufacture of
KRYSTEXXA. MVP and Duke have been granted US and foreign patents disclosing
and claiming the licensed technology and, in addition, Savient owns or co-owns
US and foreign patents and patent applications, which collectively form a
broad portfolio of patents covering the composition, manufacture and methods
of use and administration of KRYSTEXXA. Savient also supplies Oxandrin®
(oxandrolone tablets, USP) CIII in the US For more information, please visit
the Company's website at www.savient.com.

SVNT - G

Contact:
Savient Pharmaceuticals, Inc.
John P. Hamill
Senior Vice President and Chief Financial Officer
information@savient.com
(732) 418-9300

Burns McClellan
Caitlyn Murphy
cmurphy@burnsmc.com
(212) 213-0006

SOURCE Savient Pharmaceuticals, Inc.

Website: http://www.savient.com
 
Press spacebar to pause and continue. Press esc to stop.